Welcome, Guest. Please login or register.
March 29, 2024, 08:02:40 am

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55125
  • Total Topics: 4851
  • Online Today: 157
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 118
Total: 118

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: People With Liver Cancer Can Benefit From Checkpoint Immunotherapy  (Read 7356 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
People With Liver Cancer Can Benefit From Checkpoint Immunotherapy
« on: September 16, 2019, 10:54:41 am »
The PD-1 checkpoint inhibitor Keytruda (pembrolizumab) offered improved response rates for people with advanced liver cancer, although survival improvements did not meet statistical thresholds, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. Another study showed that pairing Opdivo (nivolumab) with a different type of immunotherapy improved outcomes considerably.

Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes of liver injury can lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of primary liver cancer. This type of cancer is often detected late and is difficult to treat. Liver cancer generally does not respond well to traditional chemotherapy. Keytruda and Opdivo, as well as a handful of targeted therapies that interfere with cell growth and blood vessel development, have recently been approved to treat this cancer.

For more...
https://www.hepmag.com/article/people-liver-cancer-can-benefit-checkpoint-immunotherapy

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.